Customisable DES (drug-eluting stent) shows early trial promise for Xtent
This article was originally published in Clinica
Executive Summary
Heralded as a potentially "disruptive breakthrough" in the drug-eluting stent (DES) market, a modular DES system that can have its length customised in-situ to match the patient's lesion has produced encouraging interim results in a first-in-man trial.